Financial Data and Key Metrics Changes - In 2025, the company achieved a total delivery of 596,905 vehicles, representing a 103% increase year-over-year, marking two consecutive years of doubled deliveries [5][9] - The net profit for 2025 was CNY 540 million, with a gross profit margin of 14.5%, up by 6.1% from 8.4% in 2024 [6][8] - Total revenue exceeded CNY 64 billion, reflecting a 101.3% increase compared to the previous year [8] - Cash flow from operations surpassed CNY 12 billion, an increase of CNY 4.15 billion from 2024 [8] Business Line Data and Key Metrics Changes - The company reported that it is the only startup EV company in China with monthly sales exceeding 70,000 units [5] - The gross profit margin for Q4 2025 reached a record 15% [6][8] - The company launched three new B-series models and revamped existing models, contributing to sales growth [10][12] Market Data and Key Metrics Changes - By the end of 2025, the company had established a sales and service network covering 259 cities, an increase of 31 cities from the previous year [17] - The total export volume reached 100,000 units, with the company ranking first among BEV startups in exports [6][21] - The company has expanded its international presence, with significant operations in Europe, Asia-Pacific, and South America [21] Company Strategy and Development Direction - The company aims to enhance its in-house production capabilities to mitigate raw material price fluctuations and improve cost control [26][27] - Localization of production is a strategic focus, with plans for localized production in Spain for the B10 model [34] - The company is committed to developing smart driving technology in-house, aiming to be recognized as a Tier 1 brand in this area by the end of 2026 [62] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving sales targets for 2026, despite potential market fluctuations [50][51] - The company anticipates that geopolitical tensions and oil price volatility may accelerate the adoption of new energy vehicles in Europe [68] - Management emphasized the importance of customer satisfaction and service capabilities as key areas for improvement [18] Other Important Information - The company has received recognition for its ESG governance capabilities, achieving a high rating from MSCI for three consecutive years [23] - A strategic agreement was signed with FAW Group for joint development of new energy passenger vehicles [20] Q&A Session Summary Question: Raw materials price changes and impact on GP margin - Management acknowledged the impact of raw material price increases but emphasized that cost control measures would mitigate significant effects on gross profit margins [26][27] Question: Breakdown of revenue from services and sustainability - The CNY 2.72 billion revenue includes carbon credit revenue, license fees, and export-related revenues, with expectations for growth in these areas [28][29] Question: Overseas business and localization plans - The company plans to localize production in Spain, with only 1/4 of B10 sales being produced locally, while the rest will be exported [34] Question: Q1 GP margin estimates and sales expenses - Management indicated that Q1 GP margin would likely drop due to lower sales volume, but they expect no major impact from raw material price changes [42][43] Question: Inventory levels and product mix - Current inventory levels are maintained at around 1.5 to 2 months, with a target of 600,000 sales volume for 2026, aiming for a mix of 60% new models and 40% old models [76][79]

Financial Data and Key Metrics Changes - In 2025, the total vehicle sales reached 596,905 units, an increase of 103% compared to the previous year, marking two consecutive years of doubling deliveries [3][4] - The company achieved a net profit of CNY 540 million in 2025, breaking even and becoming profitable [4][5] - Revenue exceeded CNY 64 billion, up by 101.3% year-on-year, with a gross profit margin of 14.5%, an increase of 6.1% from 8.4% in 2024 [5][6] - Cash flow from operations exceeded CNY 12 billion, up by CNY 4.15 billion compared to 2024 [5][6] - Total cash balance reached CNY 37.8 billion, an increase of CNY 13.2 billion or 50.9% [4][5] Business Line Data and Key Metrics Changes - The company launched three new B-series models and revamped existing models, contributing to strong sales performance [7][8] - The C10 model achieved over 200,000 units sold within 18 months, while the B05 and B10 models also saw significant sales shortly after their launches [6][7] - The gross profit margin for Q4 2025 reached a record 15% [4][5] Market Data and Key Metrics Changes - Leapmotor ranked first among all EV startups in China for total exports, exceeding 100,000 units in 2025 [4][20] - The company expanded its sales and service network to cover 259 cities, an increase of 31 cities from the previous year [16] - By the end of 2025, Leapmotor International established 900 sales and service outlets globally, with over 800 in Europe and Asia-Pacific [20] Company Strategy and Development Direction - The company aims to enhance in-house production capabilities to mitigate raw material price fluctuations and improve cost control [25][26] - Leapmotor is focusing on localization for its production strategy, particularly in Europe, to adapt to geopolitical changes [30][31] - The company plans to continue investing in R&D, particularly in smart driving technology, with a commitment to in-house development [48][49] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving sales targets for 2026, despite potential market fluctuations [40] - The company anticipates that the demand for new energy vehicles will continue to grow, particularly in the European market due to rising oil prices [51] - Management emphasized the importance of maintaining a balance in inventory levels to optimize sales performance [56][57] Other Important Information - Leapmotor received recognition for its ESG governance capabilities, achieving a high rating from MSCI for three consecutive years [21][22] - The company signed strategic agreements with FAW Group and other partners to enhance collaboration in R&D and production [19][50] Q&A Session Summary Question: Impact of raw material price changes on gross profit margin - Management acknowledged the pressure from raw material price increases but emphasized that cost control measures would mitigate significant impacts on gross profit margin [25][26] Question: Breakdown of revenue from services and sustainability - The CNY 2.72 billion revenue includes carbon credit revenue, license fees, and export-related revenues, with expectations for growth in these areas [27][28] Question: Overseas business and localization plans - Management confirmed that only one-fourth of B10 sales would be localized in Europe, with the rest exported, and emphasized the importance of localization for global expansion [30][31] Question: Guidance for Q1 gross profit margin and sales expenses - Management indicated that Q1 gross profit margin would likely drop due to seasonal sales volume fluctuations, while sales expenses would increase in 2026 but decrease per vehicle [34][37] Question: Sales targets for domestic and overseas markets - The company maintained its sales target of 1 million units for 2026, with a focus on Brazil and other key South American markets [40][43]

Financial Data and Key Metrics Changes - In Q4 2025, revenue rose to $85.2 million, up 43% year-over-year, reaching the upper end of guidance [11] - For the full year 2025, revenue was $183 million, representing a 41.8% year-over-year growth [11] - Gross margin in Q4 reached 40.4%, an increase of 3.6 percentage points compared to the same period in 2024 [12][13] - Full-year gross margin for 2025 was 38.3%, with expectations for continued improvement in 2026 [14] Business Line Data and Key Metrics Changes - Amazfit branded product revenue grew 51% year-over-year for the full year 2025, with Q4 sales increasing by 45.4% year-over-year [4][11] - The launch of new products like Active Max and T-Rex Ultra 2 contributed to the strong performance across both entry-level and premium segments [5][10] Market Data and Key Metrics Changes - The company reported strong execution during critical sales periods, particularly Black Friday and Christmas, enhancing brand visibility across major e-commerce channels [11] - The average selling price of products has steadily increased, providing a competitive edge against rivals [22] Company Strategy and Development Direction - The company is transitioning from a traditional wearable hardware business to a hybrid training platform, focusing on integrating hardware, training intelligence, and software [4] - Strategic partnerships with elite athletes and events like HYROX are aimed at enhancing brand credibility and visibility in the performance sports community [8][9] - Plans for 2026 include strengthening the premium product lineup and expanding the ecosystem through AI-driven training insights [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustained demand beyond seasonal trends, projecting Q1 2026 revenue between $50 million and $55 million, representing a year-over-year growth of 30%-43% [10][22] - The company is navigating macroeconomic challenges, including memory cost inflation, while maintaining a focus on cost management and operational efficiency [21] Other Important Information - The net loss attributed to Zepp Health was $6.4 million in Q4 2025, a significant improvement from an adjusted net loss of $22.5 million in Q4 2024 [18] - Cash equivalents stood at $113 million as of December 31, 2025, reflecting a strong liquidity position [19] Q&A Session Summary Question: How many new products are you planning to launch this year compared to last year? - The company plans to launch a similar number of products as last year, which was around nine [26] Question: How are you preparing for the recent spike in the U.S. dollar? - The company is not significantly affected by dollar fluctuations, as production is diversified across Asia, and the dollar is providing some tailwind [28] Question: Which specific areas do you think there are reductions in operating expenses? - Selling and marketing expenses have been front-loaded for product launches, and G&A costs have been decreasing [29]

Financial Data and Key Metrics Changes - In 2025, total revenue reached $959.5 million, a 61.4% year-over-year increase, with gross profit more than doubling [34] - Adjusted net profit was approximately $230.3 million, reflecting a 285% year-over-year growth from $59.8 million in FY 2024 [38] - The company recorded a loss of $532.4 million due to share loss and impairment from the investment in Legend Biotech [35][36] Business Line Data and Key Metrics Changes - GenScript Life Science Group revenue grew 14.8% year-over-year to $522.1 million, contributing significantly to overall growth [34] - ProBio achieved a remarkable 309.1% year-over-year growth to $388.7 million, largely due to the LaNova license deal [34] - Bestzyme's revenue grew by 7.9% year-over-year to $58 million, outperforming the industry average of 5% [34] Market Data and Key Metrics Changes - North American and European markets contributed 38% of total revenue, indicating a notable increase in international footprint [41] - Orders from first-time clients in the Life Science Group grew over 34% year-over-year, reflecting strong market demand [9] - The U.S. market maintained steady growth, while Europe achieved over 30% growth in 2025 [10] Company Strategy and Development Direction - The company aims to achieve high-quality growth while gradually improving profitability, focusing on platform innovation and ecosystem expansion [46] - Strategic investments will be made in automation and digitalization to enhance operational efficiency and cost-effectiveness [46] - The company plans to strengthen its capabilities in business synergy, globalization, and automation as key focuses for 2026 [47] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth trajectory of the GenScript Life Science Group, expecting revenue growth between 15% and 18% in 2026 [46] - The company noted that geopolitical uncertainties had a relatively minor impact on biopharmaceutical production capacity in 2025 [62] - Management highlighted the importance of maintaining market leadership and focusing on cost optimization to improve profitability [56] Other Important Information - GenScript achieved significant ESG milestones, including an upgrade to AA rating by MSCI and inclusion in the FTSE4Good index series [7] - The company reported a significant increase in R&D efficiency, achieving a 140% improvement and reducing project timelines to six months [32] Q&A Session Summary Question: Revenue recognition from LaNova deal - The company confirmed that the second milestone payment from the LaNova deal was recognized in the second half of 2025, contributing to strong organic growth [51] Question: Profitability and gross profit margin decline - Management explained that slight fluctuations in gross profit margins were due to necessary investments for global expansion and product mix shifts, with expectations for improvement in 2026 [55][56] Question: Outlook for global market share amid geopolitical uncertainties - Management expressed optimism about the long-term prospects for CRO and CDMO, citing a rebound in global biopharmaceutical investment and improved capacity utilization in China [62] Question: Development strategy for Legend Biotech - Management highlighted Legend's significant progress and profitability, stating that it will continue to evaluate options to maximize shareholder value [73] Question: Strategy to mitigate customer concerns regarding regulatory scrutiny - The company clarified that it is not classified as a genomics or gene therapy-related company and will enhance transparency and compliance to address customer concerns [75]

Financial Data and Key Metrics Changes - In 2025, the total revenue reached $959.5 million, a 61.4% year-over-year increase, with gross profit more than doubling [33] - Adjusted net profit was approximately $230 million, reflecting a 285% year-over-year growth from $59.8 million in FY 2024 [37] - Adjusted gross profit grew 12.5% year-over-year to $267.3 million, with an adjusted gross profit margin of 51.2% [39] Business Segment Data and Key Metrics Changes - The GenScript Life Science Group revenue grew 14.8% year-over-year to $522.1 million, with integrated gene-to-protein services accounting for nearly 65% of total revenue growth [33][38] - ProBio generated $388.7 million in total revenue, with a 21% organic growth excluding the LaNova deal [40] - Bestzyme's revenue grew by 7.9% year-over-year to $58 million, outperforming the industry average of 5% [33] Market Data and Key Metrics Changes - North American and European markets contributed 38% of total revenue, reflecting an enhanced international footprint [40] - Orders from first-time clients in the Life Science Group grew over 34% year-over-year, indicating strong market demand [9] - The Asia Pacific region, particularly Greater China, showed increased activities, contributing to overall growth [10] Company Strategy and Development Direction - The company aims to achieve high-quality growth while gradually improving profitability, focusing on platform innovation, ecosystem expansion, and automation [45] - Strategic investments will be made in differentiating technologies and operational efficiency improvements to enhance margins [54] - The company plans to expedite the establishment of commercial manufacturing capacity for sweet proteins, laying the foundation for international market expansion [46] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the long-term growth trajectory of the Life Science Group, anticipating revenue growth between 15% and 18% in 2026 [45] - The company noted that geopolitical uncertainties had a relatively minor impact on biopharmaceutical production capacity in 2025 [59] - Legend Biotech is expected to positively impact the company's financials in the long run, with its CAR-T franchise achieving profitability [70] Other Important Information - The company achieved significant progress in sustainability, receiving an upgraded ESG rating to AA from MSCI and being included in the FTSE4Good index series [7] - R&D investment increased significantly, with a focus on AI-powered molecular discovery and product optimization, achieving a 140% improvement in R&D efficiency [31] Q&A Session Summary Question: Revenue recognition from LaNova deal - The company confirmed that the second milestone payment from the LaNova deal was recognized in the second half of 2025, contributing to strong growth in the Life Sciences Group [50] Question: Profitability and gross profit margin decline - Management explained that gross profit fluctuations were due to necessary investments for global expansion and product mix shifts, with expectations for improved margins in 2026 through cost optimization and operational efficiency [53][54] Question: Outlook for Life Sciences business amid geopolitical uncertainties - Management expressed a highly optimistic outlook for the CRO and CDMO sectors, noting a rebound in global biopharmaceutical investment and a thriving trend in biotech R&D [59] Question: Development strategy for Legend Biotech - Management highlighted that Legend Biotech is a valuable asset, with significant progress expected to benefit the company's financials in the long run [70] Question: Strategy to mitigate customer concerns regarding regulatory scrutiny - The company clarified that it provides raw materials to gene therapy companies and is enhancing transparency and compliance to address regulatory concerns [72]

Financial Performance and Key Metrics - In 2025, the company achieved total revenue of $959.5 million, representing a 61.4% year-over-year increase, with gross profit more than doubling [33][34] - Adjusted net profit reached nearly $230 million, reflecting a 285% year-over-year growth from $59.8 million in FY 2024 [37] - The adjusted gross profit margin was stable at 51.2%, with adjusted gross profit growing 12.5% year-over-year to $267.3 million [39] Business Segment Performance - The GenScript Life Science Group generated revenue of $522.1 million, growing 14.8% year-over-year, and was identified as the growth engine and profit center [33][38] - ProBio reported total revenue of $388.7 million, with 21% organic growth excluding the LaNova deal, driven by strong customer demand for protein and antibody services [40][41] - Bestzyme's revenue grew by 7.9% year-over-year to $58 million, outperforming the industry average of 5% [33] Market Performance - The North American and European markets contributed 38% of total revenue, indicating a notable increase in the company's international footprint [41] - The Asia Pacific region, particularly Greater China, showed increased activity, contributing to the overall growth [10] Company Strategy and Industry Competition - The company aims to achieve high-quality growth while gradually improving profitability, focusing on platform leadership, ecosystem expansion, and automation-driven scale [44] - The strategy includes strengthening global partnerships, enhancing customer reach, and integrating new modalities into existing platforms [44] - The company is committed to maintaining its competitive edge through strategic investments in R&D and operational efficiency improvements [54] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the long-term growth trajectory of the CRO and CDMO sectors, citing a rebound in global biopharmaceutical investment and financing [59] - The company anticipates revenue growth for the GenScript Life Science Group to be between 15% and 18% in 2026, with an adjusted gross margin expected to reach 52% [44] Other Important Information - The company achieved significant progress in sustainability, receiving an upgraded ESG rating to AA from MSCI and being included in the FTSE4Good index series [6] - The company reported a share loss of $310.4 million related to its investment in Legend Biotech, which is expected to improve as Legend's financial position strengthens [34][37] Q&A Session Summary Question: Revenue recognition from LaNova deal - Management confirmed that the second milestone payment from the LaNova deal was recognized in the second half of 2025, contributing to strong organic growth [48][50] Question: Profitability and gross profit margin decline - Management acknowledged slight fluctuations in gross profit margins due to investments in global expansion and emphasized a focus on cost optimization and operational efficiency to improve profitability [53][54] Question: Outlook for Life Sciences business amid geopolitical uncertainties - Management expressed a highly optimistic outlook for the CRO and CDMO sectors, noting a rebound in global biopharmaceutical investment and improved capacity utilization in China [59][62] Question: Future strategy for Legend Biotech - Management highlighted Legend Biotech's significant progress and profitability, stating that they are not planning to establish new biotech companies but will leverage existing platforms to accelerate drug discovery [64][66] Question: Mitigating customer concerns regarding regulatory scrutiny - Management clarified that the company provides raw materials to gene therapy companies and is enhancing transparency and compliance to address regulatory concerns [72]

Financial Data and Key Metrics Changes - Full year revenue increased by 376% to $4.5 million for the 2025 fiscal year, with Q4 revenue increasing 70% year-over-year to $0.9 million [8] - Total transaction volume for the full year increased to $116.1 million, and gross profit for the year increased to $2.5 million [9] - Cash and cash equivalents at year-end were approximately $7.8 million, representing a 149% year-over-year increase [10] Business Line Data and Key Metrics Changes - Growth in the home buying segment was driven by strong year-over-year growth in the mortgage brokerage operation and the contribution from the Prevu acquisition [15] - The technology services segment saw meaningful growth in AiChat subscription revenue, adding recurring software subscription revenue to the overall revenue stream [16] Market Data and Key Metrics Changes - The company is expanding its market presence, with the Prevu acquisition adding operations in 13 additional states and Washington, D.C. [30] - The upcoming acquisition of InstaMortgage is expected to enhance lending capabilities and deepen mortgage participation [39] Company Strategy and Development Direction - The company aims to capture more of the home buying transaction across real estate, mortgage, and title, with a focus on integrating services on a single platform [14] - The strategy emphasizes reducing fragmentation in the home buying process and improving customer experience through AI-enabled workflows [22] Management's Comments on Operating Environment and Future Outlook - Management views 2025 as a year of growth and improved financial flexibility, with a focus on investing in the AI platform and strategic acquisitions [11] - The company is committed to disciplined growth, ensuring that capital allocation supports long-term value creation rather than undisciplined expansion [26][27] Other Important Information - The company is working on regulatory approvals for the InstaMortgage acquisition, which is expected to close in late Q1 or early Q2 2026 [35][36] - The integration of Prevu and the upcoming acquisition of InstaMortgage are seen as critical milestones in building a comprehensive platform for home buyers [29][30] Q&A Session Summary Question: What are the main drivers behind revenue growth? - Revenue growth was driven by strong performance in the mortgage brokerage operation and contributions from the Prevu acquisition [15] Question: How is the company thinking about capital allocation going forward? - The company aims to preserve flexibility and liquidity while focusing on disciplined growth and strategic capital deployment [24][27] Question: What operational or regulatory steps are needed for the InstaMortgage acquisition? - The company is working with state regulators to ensure compliance and hopes to close the acquisition soon [35][36] Question: How does the company plan to achieve profitability? - The pathway to profitability involves integrating more services and growing the lifetime value per customer while maintaining disciplined growth [44][46]

Financial Data and Key Metrics Changes - Vista Gold reported a net loss of $7.5 million for the year ended December 31, 2025, compared to a net income of $11.2 million for 2024, largely due to a $16.9 million gain recognized in 2024 related to a royalty interest grant [8][12] - The company ended 2025 with cash on hand of $13.6 million and completed an equity offering with net proceeds of $41.9 million, positioning it well financially for future projects [7][19] - Corporate administration expenses remained steady at $3.6 million in 2025, compared to $3.7 million in 2024 [10] Business Line Data and Key Metrics Changes - Exploration and other expenses for the Mt Todd project were $5.6 million in 2025, up from $3.5 million in 2024, primarily due to the completion of the feasibility study [9] - The feasibility study completed in July 2025 indicated a new operational vision for Mt Todd, with a projected net present value (NPV) of $1.1 billion at a gold price of $2,500 per ounce [11] Market Data and Key Metrics Changes - Vista Gold's shares increased almost 252% in 2025 compared to the year-end 2024, reflecting both the rise in gold prices and market support for the Mt Todd feasibility study [18] - The current market capitalization of Vista Gold is approximately $300 million following the recent financing [19] Company Strategy and Development Direction - The company is focused on advancing the Mt Todd Gold Project, with plans to begin detailed engineering and design in 2027, marking the start of a 27-month period leading to first gold production [17][32] - Vista Gold aims to build a technical and organizational foundation for project execution, including hiring key personnel and modifying existing permits to align with the feasibility study [16][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the intrinsic value of the Mt Todd project, anticipating it will generate $300 million of free cash flow annually at a conservative gold price of $3,300 per ounce [17] - The company remains committed to safety and environmental stewardship, having achieved four years without a workplace incident [15] Other Important Information - The feasibility study demonstrated a path to near-term production with lower initial capital costs and reduced operational risks [11] - The company is actively engaging with stakeholders and has a strong safety culture, as evidenced by zero reportable environmental incidents [15] Q&A Session Summary Question: Outlook on discount rates for projects in safe jurisdictions - Management indicated that projects like Mt Todd in the Northern Territory will likely see better discount rates and financing conditions due to its tier one jurisdiction status [24] Question: Concerns about input cost changes due to rising gold prices - Management noted that while modest increases in equipment costs are expected, there are currently no significant changes that would affect the Mt Todd project negatively [25][26] Question: Timeline for gold production and potential partnerships - Management stated that the timeline for first gold production is dependent on the start of detailed engineering and design, expected in mid-2027 [32] Question: Financing outlook and shareholder dilution concerns - Management explained that financing could take various forms, with a significant portion of the project potentially financed through debt, aiming for an accretive outcome for shareholders despite the need for additional equity [40][41] Question: Information on Sun Valley Gold's share sales - Management clarified that the sales were part of a transition to a family office and not necessarily indicative of a loss of confidence in Vista Gold [42][43]

Financial Data and Key Metrics Changes - Total net revenue for the full year 2025 was $164.6 million, a decrease of $19.6 million or 10.7% from $184.2 million in 2024 [5] - Net income was $41.8 million, down from $61.6 million in 2024, representing a decrease of $19.8 million or 32.2% [10] - Diluted earnings per share were $0.74 compared to $2.48 in 2024 [10] - Book value per share increased to $22.20 from $20.45, an increase of $1.75 or about 8.6% [11] Business Line Data and Key Metrics Changes - Product sales decreased by $12.4 million or 9.6% to $116.9 million, with unit sales down to 1,703 from 2,129 in 2024, a decline of about 20% [5] - Consumer loan interest income increased to $43.7 million, up $2.5 million or 6.1% compared to 2024, driven by growth in the consumer loan portfolio [7] - The mobile home park note portfolio decreased by $9.1 million to $199.1 million due to early payoffs [8] Market Data and Key Metrics Changes - The manufactured housing industry faced headwinds, with industry shipments running at an annualized rate of approximately 106,000 last year [14] - Occupancy rates in mobile home parks, particularly in large metropolitan areas, remained very high [16] - The affordability gap between manufactured homes and site-built homes continues to widen, with manufactured homes averaging about $98.5 per sq ft compared to double that for site-built construction [14] Company Strategy and Development Direction - The company is focused on serving the approximately 63 million U.S. households with annual incomes below $75,000 [14] - There is a strategic emphasis on workforce housing and data center opportunities, with over 500 houses already ordered in this space [19] - The company is evaluating its share repurchase program and plans to continue to use its balance sheet strength to repurchase shares opportunistically [21] Management's Comments on Operating Environment and Future Outlook - Management noted that the manufactured housing industry is experiencing persistent housing affordability problems, falling consumer confidence, and tariff-driven price increases [14] - The company expects continued growth in its consumer loan portfolio and maintains strong credit quality, with over 97% of loans current [16] - Management expressed optimism about the potential for a good year in 2026, despite current challenges [85] Other Important Information - The company repurchased 346,000 shares last year and initiated a $10 million buyback program [17] - The acquisition of AmeriCasa added a consumer loan portfolio and retail location, although management's excitement about the acquisition has diminished [81][82] Q&A Session Summary Question: Clarification on ASP and gross margin changes - Management explained that the ASP per section dropped about 15% sequentially, but the ASP increased 12% due to selling more double-wides, which have higher unit profitability [25] Question: Demand perspective for commercial sales - Management noted that workforce housing opportunities in rural areas are robust, but general demand for commercial sales remains weak due to high park rents [33][34] Question: Update on Austin project and regulatory hurdles - Management indicated that the wastewater treatment plant is substantially delivered, and they expect to begin putting homes in the Austin project in 2026 [70][71] Question: Future plans for the Georgia plant - Management stated that they are considering either turning around the Georgia plant or disposing of it, as it has not contributed to earnings in several years [80] Question: Update on AmeriCasa acquisition - Management mentioned that the acquisition has not met initial expectations, but they are continuing to install software and have gained some valuable middle management [81][82]

Financial Data and Key Metrics Changes - Full year revenue increased by 376% to $4.5 million for the 2025 fiscal year, with Q4 revenue increasing 70% year-over-year to $0.9 million [8] - Total transaction volume for the year increased to $116.1 million, and gross profit rose to $2.5 million [9] - Cash and cash equivalents at year-end were approximately $7.8 million, reflecting a 149% year-over-year increase [10] Business Line Data and Key Metrics Changes - Growth in the home buying segment was driven by strong performance in the mortgage brokerage operation and the contribution from the Prevu acquisition [15] - The technology services segment, particularly AiChat subscription revenue, also saw significant growth, contributing to a more diversified revenue mix [16] Market Data and Key Metrics Changes - The company is expanding its market presence, with the Prevu acquisition adding operations in 13 additional states and Washington, D.C. [30] - The upcoming acquisition of InstaMortgage is expected to enhance lending capabilities and deepen mortgage participation [39] Company Strategy and Development Direction - The company aims to capture more of the home buying transaction across real estate, mortgage, and title services, focusing on integrating these services into a single platform [14] - The strategy emphasizes reducing fragmentation in the home buying process, improving customer experience through AI-enabled workflows [22] Management's Comments on Operating Environment and Future Outlook - Management views 2025 as a year of growth and improved financial flexibility, with a focus on investing in the AI platform and strategic acquisitions [11] - The pathway to profitability is linked to disciplined growth and the integration of additional services to enhance customer lifetime value [44][46] Other Important Information - The company is focused on maintaining capital flexibility while pursuing growth opportunities, with a methodical approach to capital allocation [24] - The integration of Prevu and the upcoming InstaMortgage acquisition are seen as critical milestones in building a comprehensive platform [29] Q&A Session Summary Question: What are the main drivers behind revenue growth? - Revenue growth was driven by strong performance in the mortgage brokerage operation and the contribution from the Prevu acquisition [15] Question: How is the company thinking about capital allocation going forward? - The company aims to preserve flexibility and liquidity while being methodical in capital allocation to support growth and strategic acquisitions [24] Question: What needs to happen operationally or regulatorily for the InstaMortgage acquisition? - The company is working with state regulators to ensure compliance and hopes to close the acquisition in late Q1 or early Q2, subject to approvals [36]